Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: Possible application to enhance T cell function

International Immunology

Volumn 19, Issue 7, 2007, Pages 881-890

  Terawaki, Seigo ^a   Tanaka, Yoshimasa ^a,b   Nagakura, Tomokazu ^a   Hayashi, Tamon ^c   Shibayama, Shiro ^c   Muroi, Kaori ^a   Okazaki, Taku ^a   Mikami, Bunzo ^a   Garboczi, David N ^d   Honjo, Tasuku ^a   Minato, Nagahiro ^a  

^a KYOTO UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c ONO PHARMACEUTICAL CO   (Japan)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Affinity; Cancer; Immunoreceptor; Infection; Tetramer

Indexed keywords

CHIMERIC PROTEIN; LIGAND; MEMBRANE PROTEIN; MONOMER; PROGRAMMED CELL DEATH 1; PROGRAMMED CELL DEATH LIGAND 1; TETRAMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; IN VITRO STUDY; LIGAND BINDING; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE; VIRUS INFECTION;

ANIMALS; ANTIGENS, CD80; ANTIGENS, SURFACE; APOPTOSIS REGULATORY PROTEINS; CELL LINE; CELLS, CULTURED; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; PEPTIDES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SPLEEN; T-LYMPHOCYTES;

EID: 34547748421     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxm059     Document Type: Article

References (45)

1. Chambers, C. A. 2001. The expanding world of co-stimulation: The two-signal model revisited. Trends Immunol. 22:217.
2. Greenwald, R. J., Freeman, G. J. and Sharpe, A. H. 2005. The B7 family revisited. Annu. Rev. Immunol. 23:515.
3. Pages, F., Ragueneau, M., Rottapel, R. et al. 1994. Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature 369:327.
4. Prasad, K. V., Cai, Y. C., Raab, M. et al. 1994. T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. Proc. Natl Acad. Sci. USA 91:2834.
5. Stein, P. H., Fraser, J. D. and Weiss, A. 1994. The cytoplasmic domain of CD28 is both necessary and sufficient for costimulation of interleukin-2 secretion and association with phosphatidylinositol 3′-kinase. Mol. Cell. Biol. 14:3392.
6. Schneider, H., Schwartzberg, P. L. and Rudd, C. E. 1998. Resting lymphocyte kinase (Rlk/Txk) phosphorylates the YVKM motif and regulates PI 3-kinase binding to T-cell antigen CTLA-4. Biochem. Biophys. Res. Commun. 252:14.
7. Schneider, H., da Rocha Dias, S., Hu, H. and Rudd, C. E. 2001. A regulatory role for cytoplasmic YVKM motif in CTLA-4 inhibition of TCR signaling. Eur. J. Immunol. 31:2042.
8. Schwartz, J. C., Zhang, X., Nathenson, S. G. and Almo, S. C. 2002. Structural mechanisms of costimulation. Nat. Immunol. 3:427.
9. Zhang, X., Schwartz, J. C., Guo, X. et al. 2004. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 20:337.
10. Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T. and Honjo, T. 2001. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl Acad. Sci. USA 98:13866.
11. Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H. and Riley, J. L. 2004. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173:945.
12. Saunders, P. A., Hendrycks, V. R., Lidinsky, W. A. and Woods, M. L. 2005. PD-L2:PD-1 involvement in Tcell proliferation, cytokine production, and integrin-mediated adhesion. Eur. J. Immunol. 35:3561.
13. Dong, H., Zhu, G., Tamada, K. and Chen, L. 1999. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5:1365.
14. Freeman, G. J., Long, A. J., Iwai, Y. et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192:1027.
15. Latchman, Y., Wood, C. R., Chernova, T. et al. 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2:261.
16. Tseng, S. Y., Otsuji, M., Gorski, K. et al. 2001. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 193:839.
17. Iwai, Y., Terawaki, S., Ikegawa, M., Okazaki, T. and Honjo, T. 2003. PD-1 inhibits antiviral immunity at the effector phase in the liver. J. Exp. Med. 198:39.
18. Ansari, M. J., Salama, A. D., Chitnis, T. et al. 2003. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198:63.
19. Liang, S. C., Latchman, Y. E., Buhlmann, J. E. et al. 2003. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 33:2706.
20. Salama, A. D., Chitnis, T., Imitola, J. et al. 2003. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 198:71.
21. Ishida, M., Iwai, Y., Tanaka, Y. et al. 2002. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol. Lett. 84:57.
22. Nishimura, H., Nose, M., Hiai, H., Minato, N. and Honjo, T. 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 11:141.
23. Nishimura, H., Okazaki, T., Tanaka, Y. et al. 2001. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319.
24. Okazaki, T., Tanaka, Y., Nishio, R. et al. 2003. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med. 9:1477.
25. Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T. and Minato, N. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99:12293.
26. Curiel, T. J., Wei, S., Dong, H. et al. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9:562.
27. Strome, S. E., Dong, H., Tamura, H. et al. 2003. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 63:6501.
28. Iwai, Y., Terawaki, S. and Honjo, T. 2005. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 17:133.
29. Hirano, F., Kaneko, K., Tamura, H. et al. 2005. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65:1089.
30. Barber, D. L., Wherry, E. J., Masopust, D. et al. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682.
31. Day, C. L., Kaufmann, D. E., Kiepiela, P. et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350.
32. Trautmann, L., Janbazian, L., Chomont, N. et al. 2006. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12:1198.
33. Petrovas, C., Casazza, J. P., Brenchley, J. M. et al. 2006. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J. Exp. Med. 203:2281.
34. Schatz, P. J. 1993. Use of peptide libraries to map the substrate specificity of a peptide-modifying enzyme: A 13 residue consensus peptide specifies biotinylation in Escherichia coli. Biotechnology (N. Y.) 11:1138.
35. Altman, J. D., Moss, P. A., Goulder, P. J. et al. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94.
36. Sha, W. C., Nelson, C. A., Newberry, R. D., Kranz, D. M., Russell, J. H. and Loh, D. Y. 1988. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature 335:271.
37. Evans, E. J., Esnouf, R. M., Manso-Sancho, R. et al. 2005. Crystal structure of a soluble CD28-Fab complex. Nat. Immunol. 6:271.
38. Okazaki, T., Otaka, Y., Wang, J. et al. 2005. Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b-/-Pdcd1-/-mice. J. Exp. Med. 202:1643.
39. Wang, J., Yoshida, T., Nakaki, F., Hiai, H., Okazaki, T. and Honjo, T. 2005. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc. Natl Acad. Sci. USA 102:11823.
40. Dong, H., Strome, S. E., Salomao, D. R. et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med. 8:793.
41. Konishi, J., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka-Akita, H. and Nishimura, M. 2004. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin. Cancer Res. 10:5094.
42. Ohigashi, Y., Sho, M., Yamada, Y. et al. 2005. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res. 11:2947.
43. Gold, L. and Stormo, G. D. 1990. High-level translation initiation. Methods Enzymol. 185:89.
44. Varenne, S., Buc, J., Lloubes, R. and Lazdunski, C. 1984. Translation is a non-uniform process. Effect of tRNA availability on the rate of elongation of nascent polypeptide chains. J. Mol. Biol. 180:549.
45. Nishimura, H. and Honjo, T. 2001. PD-1: An inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 22:265.